Preclinical studies demonstrate anti-IGF1R antibodies inhibit tumor cell growth in xenograft models of osteosarcoma, however, mutations in the IGF1R gene and changes in expression of IGF1R do not appear to be the driving force behind response to anti-IGF1R antibody therapy. The gene discussed is IGF1R; the disease is neoplasm.